A detailed history of Arizona State Retirement System transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Arizona State Retirement System holds 27,924 shares of RVMD stock, worth $1.03 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
27,924
Previous 28,384 1.62%
Holding current value
$1.03 Million
Previous $814,000 10.44%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

SELL
$26.56 - $33.55 $12,217 - $15,432
-460 Reduced 1.62%
27,924 $899,000
Q4 2023

Jan 24, 2024

BUY
$18.35 - $34.12 $132,028 - $245,493
7,195 Added 33.96%
28,384 $814,000
Q3 2023

Nov 06, 2023

BUY
$25.17 - $35.05 $7,903 - $11,005
314 Added 1.5%
21,189 $586,000
Q2 2023

Aug 01, 2023

SELL
$20.28 - $27.0 $35,449 - $47,196
-1,748 Reduced 7.73%
20,875 $558,000
Q1 2023

Apr 27, 2023

BUY
$20.76 - $30.09 $110,048 - $159,507
5,301 Added 30.6%
22,623 $490,000
Q4 2022

Feb 07, 2023

BUY
$17.68 - $25.53 $17,874 - $25,810
1,011 Added 6.2%
17,322 $412,000
Q3 2022

Nov 07, 2022

BUY
$17.46 - $26.0 $75,584 - $112,554
4,329 Added 36.13%
16,311 $322,000
Q2 2022

Jul 28, 2022

SELL
$14.54 - $27.17 $14,031 - $26,219
-965 Reduced 7.45%
11,982 $234,000
Q1 2022

May 04, 2022

BUY
$17.31 - $26.4 $1,280 - $1,953
74 Added 0.57%
12,947 $330,000
Q4 2021

Feb 04, 2022

SELL
$24.35 - $33.7 $3,165 - $4,381
-130 Reduced 1.0%
12,873 $324,000
Q3 2021

Nov 12, 2021

BUY
$23.95 - $33.41 $5,987 - $8,352
250 Added 1.96%
13,003 $358,000
Q2 2021

Aug 02, 2021

BUY
$29.0 - $47.44 $201,724 - $329,992
6,956 Added 119.99%
12,753 $405,000
Q1 2021

May 06, 2021

BUY
$37.21 - $54.43 $2,307 - $3,374
62 Added 1.08%
5,797 $266,000
Q4 2020

Jan 28, 2021

BUY
$30.19 - $45.49 $173,139 - $260,885
5,735 New
5,735 $227,000

Others Institutions Holding RVMD

About Revolution Medicines, Inc.


  • Ticker RVMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,697,600
  • Market Cap $3.24B
  • Description
  • Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...
More about RVMD
Track This Portfolio

Track Arizona State Retirement System Portfolio

Follow Arizona State Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arizona State Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on Arizona State Retirement System with notifications on news.